Andrographolide enhances TRAIL-induced apoptosis in bladder cancer cells by upregulating death receptors through a p53-mediated mechanism and suppressing the NF-κB pathway. Andrographolide works synergistically with TRAIL to induce apoptosis in bladder cancer cells by increasing expression of death receptors and decreasing expression of anti-apoptotic proteins regulated by NF-κB. The study suggests that combining andrographolide with TRAIL may be a potential therapeutic strategy for bladder cancer.
Original Description:
Andrographolide Enhances TRAIL Induced Apoptosis via p53-Mediated Death
Original Title
Andrographolide Enhances TRAIL Induced Apoptosis via p53-Mediated Death
Andrographolide enhances TRAIL-induced apoptosis in bladder cancer cells by upregulating death receptors through a p53-mediated mechanism and suppressing the NF-κB pathway. Andrographolide works synergistically with TRAIL to induce apoptosis in bladder cancer cells by increasing expression of death receptors and decreasing expression of anti-apoptotic proteins regulated by NF-κB. The study suggests that combining andrographolide with TRAIL may be a potential therapeutic strategy for bladder cancer.
Andrographolide enhances TRAIL-induced apoptosis in bladder cancer cells by upregulating death receptors through a p53-mediated mechanism and suppressing the NF-κB pathway. Andrographolide works synergistically with TRAIL to induce apoptosis in bladder cancer cells by increasing expression of death receptors and decreasing expression of anti-apoptotic proteins regulated by NF-κB. The study suggests that combining andrographolide with TRAIL may be a potential therapeutic strategy for bladder cancer.